Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).

Affiliation auteurs!!!! Error affiliation !!!!
TitreAccumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).
Type de publicationJournal Article
Year of Publication2019
AuteursRousseau B, Boukerma AKhaled, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim SChong Hun, Bachet J-B, Mazard T, Louvet C, Chibaudel B, Diaz LA, Vernerey D, Andre T, Hulin A
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.3121